The Attitudes of Brazilian Breast Surgeons on Axillary Management in Early Breast Cancer-10 Years After the ACOSOG Z0011 Trial First Publication
Overview
Authors
Affiliations
Purpose: To evaluate the impact of the ACOSOG Z0011 trial on axillary breast cancer surgery management in Brazil following publication of that study (2010) and again in 2020.
Patients And Methods: A survey of members of the Brazilian Society of Mastology.
Results: Of 1627 breast surgeons, 799 (49.1%) completed and returned the questionnaire. For patients with the Z11 inclusion criteria, following detection of a positive sentinel lymph node (SLN), axillary dissection (AD) was recommended by 99.2% of respondents before publication of the study, 47.5% in 2010 and 18.5% in 2020 (p < 0.001). In breast-conserving surgery, if there were micro-metastases, 2.6% would perform AD, 30.3% axillary radiotherapy, and 67.1% no additional axillary treatment, while with macro-metastases, these proportions were 21.3%, 52.2%, and 26.5%, respectively. In cases of mastectomy and of nodal extracapsular extension, 43.4% and 36% of surgeons, respectively, recommended AD. For clinically negative axilla and suspicious findings at ultrasonography, 69% of the surgeons would apply the Z11 approach. Most applied the Z11 criteria in cases of younger patients (83.6%) and triple-negative and/or HER2 positive tumors (74%). AD was significantly more likely to be recommended by surgeons who did not work in academic institutes, who worked in locations other than capital cities, who were not board-certified, and who were ≥ 50 years old.
Conclusions: This survey revealed substantial changes in axillary surgery management in cN0/pathologically positive SLN, particularly following publication of the updated Z11 results and other similar studies. A better education environment and long-term follow-up were factors associated with the incorporation of Z11-related changes in practice.
Research gaps in sentinel lymph node biopsy in breast cancer.
Hamdy O Oncologist. 2024; 29(9):e1101-e1103.
PMID: 38837063 PMC: 11379629. DOI: 10.1093/oncolo/oyae133.
Freitas-Junior R, de Oliveira V, Frasson A, Cavalcante F, Mansani F, Mattar A BMC Cancer. 2022; 22(1):1201.
PMID: 36419031 PMC: 9682792. DOI: 10.1186/s12885-022-10250-x.
Zhao F, Cai C, Liu M, Xiao J Front Endocrinol (Lausanne). 2022; 13:881761.
PMID: 35992122 PMC: 9388849. DOI: 10.3389/fendo.2022.881761.